Movement Alert｜Innovent Biologics Rises 3.19% in Regular Trading, Eli Lilly Partnership and Mazdutide Insurance Review Catalysts Continue

Market Focus

Jul 06

On July 6, Innovent Biologics rose 3.19% in regular trading, trading at HKD 91.35/share, with turnover of HKD 416 million, extending its recent strong momentum.

On the news front, multiple catalysts continue to drive sentiment. On June 30, Innovent signed a commercialization agreement with Eli Lilly for CDK4/6 inhibitor Verzenios (abemaciclib) in mainland China, granting Innovent exclusive rights to import, market, and distribute the drug, strengthening its breast cancer commercial portfolio. Additionally, core product mazdutide passed the National Healthcare Security Administration's preliminary review for medical insurance catalog inclusion on June 29, a key step toward reimbursement coverage. The company also launched its South China warehouse on July 1, further enhancing supply chain capabilities.

Within the Biotechnology sector, broad strength provided additional support. Among peers, 3SBio rose 5.06%, Remegen rose 5.01%, SKB Bio rose 3.01%, Akeso rose 2.83%, and BeiGene rose 1.64%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1116662337"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116662337\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116662337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116662337","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Rises 3.19% in Regular Trading, Eli Lilly Partnership and Mazdutide Insurance Review Catalysts Continue","media":"Market Focus","content":"<p><p>On July 6, Innovent Biologics rose 3.19% in regular trading, trading at HKD 91.35/share, with turnover of HKD 416 million, extending its recent strong momentum.</p><p>On the news front, multiple catalysts continue to drive sentiment. On June 30, Innovent signed a commercialization agreement with Eli Lilly for CDK4/6 inhibitor Verzenios (abemaciclib) in mainland China, granting Innovent exclusive rights to import, market, and distribute the drug, strengthening its breast cancer commercial portfolio. Additionally, core product mazdutide passed the National Healthcare Security Administration's preliminary review for medical insurance catalog inclusion on June 29, a key step toward reimbursement coverage. The company also launched its South China warehouse on July 1, further enhancing supply chain capabilities.</p><p>Within the Biotechnology sector, broad strength provided additional support. Among peers, 3SBio rose 5.06%, Remegen rose 5.01%, SKB Bio rose 3.01%, Akeso rose 2.83%, and BeiGene rose 1.64%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Rises 3.19% in Regular Trading, Eli Lilly Partnership and Mazdutide Insurance Review Catalysts Continue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Rises 3.19% in Regular Trading, Eli Lilly Partnership and Mazdutide Insurance Review Catalysts Continue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 09:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, Innovent Biologics rose 3.19% in regular trading, trading at HKD 91.35/share, with turnover of HKD 416 million, extending its recent strong momentum.</p><p>On the news front, multiple catalysts continue to drive sentiment. On June 30, Innovent signed a commercialization agreement with Eli Lilly for CDK4/6 inhibitor Verzenios (abemaciclib) in mainland China, granting Innovent exclusive rights to import, market, and distribute the drug, strengthening its breast cancer commercial portfolio. Additionally, core product mazdutide passed the National Healthcare Security Administration's preliminary review for medical insurance catalog inclusion on June 29, a key step toward reimbursement coverage. The company also launched its South China warehouse on July 1, further enhancing supply chain capabilities.</p><p>Within the Biotechnology sector, broad strength provided additional support. Among peers, 3SBio rose 5.06%, Remegen rose 5.01%, SKB Bio rose 3.01%, Akeso rose 2.83%, and BeiGene rose 1.64%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1116662337","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116662337","pubTimestamp":1783302161,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, Innovent Biologics rose 3.19% in regular trading, trading at HKD 91.35/share, with turnover of HKD 416 million, extending its recent strong momentum.On the news front, multiple catalysts...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动静快讯|信达生物常规交易涨3.19%礼来合伙及Mazdutide保险审查催化剂持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On July 6, Innovent Biologics rose 3.19% in regular trading, trading at HKD 91.35/share, with turnover of HKD 416 million, extending its recent strong momentum.On the news front, multiple catalysts continue to drive sentiment. On June 30, Innovent signed a commercialization agreement with Eli Lilly for CDK4/6 inhibitor Verzenios (abemaciclib) in mainland China, granting Innovent exclusive rights to import, market, and distribute the drug, strengthening its breast cancer commercial portfolio. Additionally, core product mazdutide passed the National Healthcare Security Administration's preliminary review for medical insurance catalog inclusion on June 29, a key step toward reimbursement coverage. The company also launched its South China warehouse on July 1, further enhancing supply chain capabilities.Within the Biotechnology sector, broad strength provided additional support. Among peers, 3SBio rose 5.06%, Remegen rose 5.01%, SKB Bio rose 3.01%, Akeso rose 2.83%, and BeiGene rose 1.64%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}